#India #Bengaluru #Biocon #Biosimilar #Pertuzumab

Significant Step for Biosimilars: Biocon's Pertuzumab Approved

In an important development for the biopharmaceutical landscape, Biocon Biologics Limited has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its Pertuzumab biosimilar, Pebrilzo®. This marks a notable advancement as it is the first biosimilar to achieve such a status under the EMA's newly tailored clinical development framework.

The Context

This positive recommendation is crucial, as it comes after a thorough evaluation of the marketing application submitted by Biocon Biologics Ireland Limited, a subsidiary of Biocon Biologics. Now, the European Commission will make a final decision on the approval of Pebrilzo®.

With this step, Pebrilzo® aims to improve patient access to effective biological therapies for HER2-positive breast cancer, addressing a significant unmet medical need across Europe. The approval process signifies a growing regulatory confidence in the advanced analytical and clinical-pharmacological data that support the assessment of biosimilar therapies.

Insights from Leadership

Shreehas Tambe, CEO and Managing Director of Biocon, highlighted the importance of this achievement: “The positive CHMP opinion is a crucial step in broadening access to biological therapies for patients with HER2-positive breast cancer in Europe. Our Pertuzumab biosimilar represents not only a milestone in the evolution of biosimilar science but also showcases the increasing regulatory trust in modern analytical and pharmacological evidence.”

What is Pebrilzo®?

Pebrilzo® is a monoclonal antibody that selectively targets the human epidermal growth factor receptor 2 (HER2). This therapeutic mechanism is designed to inhibit the proliferation of tumor cells that overexpress HER2, thereby providing an effective treatment strategy for patients diagnosed with this aggressive form of cancer.

It is approved for use in conjunction with trastuzumab and chemotherapy for neoadjuvant treatment in adults with HER2-positive, locally advanced, inflammatory, or early breast cancer, particularly where there is a high risk of recurrence. Furthermore, Pebrilzo® is indicated alongside trastuzumab and docetaxel for adult patients with HER2-positive, metastatic, or locally recurrent inoperable breast cancer who have not previously received anti-HER2 therapy.

Clinical Evidence

Comprehensive orthogonal analytical studies regarding the structure and function of Pebrilzo® demonstrated its comparability to the reference biological product. The comparative clinical pharmacokinetic data revealed no clinically meaningful differences in quality, safety, or efficacy between Pebrilzo® and its reference product.

About Biocon Limited

Founded in Bengaluru, India, Biocon Limited (BSE: 532523) (NSE: BIOCON) is a global biopharmaceutical organization dedicated to providing patients with access to affordable and transformative medicines. As a leader in developing biosimilars and generics, Biocon addresses the critical healthcare challenges presented by chronic and non-communicable diseases. The company has launched 12 biosimilars and over 30 generic formulations across international markets and is currently advancing its research and development pipeline, which includes more than 20 biosimilar candidates.

Leveraging an integrated lab-to-patient model, Biocon combines research, development, and manufacturing capabilities to ensure reliable and scalable drug supply. The company operates in over 120 countries and has earned recognition for its commitment to sustainable growth, being included in the SP Global Sustainability Yearbook for four consecutive years as of 2026.

For more information, visit Biocon's official website and follow them on social media.